ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Catty, Pryzbyl indicated that the earning reports will be clouded somewhat by the (one time) wind up expenses of the merger. There will be additional explanations within the filing. Once they get through the merger related numbers and see what remains for the company moving forward, Balance sheet, no debt, they own the manufacturing plants etc... and start comparing it to companies such as IGI laboratories with debt, much smaller manufacturing capabilities and smaller revenues and no bio-t-gel type revenues in the wings,they will realize that the company is positioned for steady growth.

Each quarter that we distance ourselves from Biosante the company balance sheet and revenues will look that much stronger.

Seeing that IGI is trading at $63 million range, and still losing money, in debt etc..., If the markets start comparative shopping and once Teva gets ANDA approval and marketing date, we should be crossing the $300 million market into small cap territory.